title: Characteristics of older newly diagnosed cancer patients refusing cancer treatments.
abstract: OBJECTIVE
  With the aging of the population, there will be an increase in the number of older adults diagnosed with cancer. Little is known about the characteristics of older newly diagnosed cancer patients who refuse cancer treatment and how often they refuse. The aim of this paper was to describe the health and functional status characteristics of patients who refused cancer treatment.
  
  
  METHODS
  A prospective pilot study on health and vulnerability in older newly diagnosed cancer patients was conducted in the Segal Cancer Centre, Jewish General Hospital, Montreal, Canada. One hundred-twelve patients agreed to participate (response 72%). Health and functional status were assessed during the baseline interview; information on cancer treatment was obtained from the medical chart at baseline, 3 and 6 months follow-up. Descriptive techniques such as frequencies and means were used to describe the health and functional status of patients who refused treatment.
  
  
  RESULTS
  Of the 112 participants, 17 (15.2%) refused cancer treatment partially or completely. Of those 17, 15 were women and 2 men. Fifteen participants refused a part of their treatment upfront. Two refused all further treatment after severe toxicity. The majority of participants refusing cancer treatment were women with breast cancer and they mostly refused adjuvant chemotherapy. Participants who refused often lived alone, were less often married/living common-law, had activities of daily living disability, and often had early disease.
  
  
  CONCLUSIONS
  The majority of older newly diagnosed cancer patients underwent the recommended cancer treatment but partial or complete cancer treatment refusal in older newly diagnosed cancer patients was not uncommon.
authors.affiliation: McGill University-Université de Montréal Solidage Research Group on Frailty and Aging, Montreal, QC, Canada. martine.puts@utoronto.ca
authors.forename: Martine T E
authors.initials: MT
authors.lastname: Puts
authors.forename: Johanne
authors.initials: J
authors.lastname: Monette
authors.forename: Veronique
authors.initials: V
authors.lastname: Girre
authors.forename: Christina
authors.initials: C
authors.lastname: Wolfson
authors.forename: Michèle
authors.initials: M
authors.lastname: Monette
authors.forename: Gerald
authors.initials: G
authors.lastname: Batist
authors.forename: Howard
authors.initials: H
authors.lastname: Bergman
mesh_terms: D000203:Activities of Daily Living; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant / Q000009:adverse effects / Q000379:methods; D005260:Female; D005500:Follow-Up Studies; D006304:Health Status; D006801:Humans; D008297:Male; D009369:Neoplasms / Q000188:drug therapy*; D010865:Pilot Projects; D011446:Prospective Studies; D016312:Treatment Refusal / Q000523:psychology*
chemical_list: D000970:Antineoplastic Agents